ROCKVILLE, Md., Nov. 1, 2021- Integrated BioTherapeutics Inc. (IBT) and Integral Molecular have collaboratively engineered proteins for developing broadly protective vaccines for Ebola and related viruses. Development of this next-generation vaccine was enabled by the combined application of IBT discovered neutralizing Ebola antibodies and Integral Molecular’s GeneCanvas protein engineering platform to identify glycoprotein mutations that make the Ebola virus vulnerable to immune detection.